Ebola vaccine provides high protection against disease

Staff Correspondent | Published: 20:28 pm, 06 Jan 2017, Fri

Ebola vaccine provides high protection against disease

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year. The vaccine, called rVSV-ZEBOV, was studied in a trial involving 11,841 people in Guinea during 2015. Among the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination. In comparison, there were 23 cases 10 days or more after vaccination among those who did not receive the vaccine. The trial was led by the World Health Organisation (WHO), together with Guinea’s Ministry of Health and other international partners.